Showing results (3051-3060 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|March 29, 2025
Defining Biological and Clinical Plausibility: The DICSA Framework for Protocolized Assessment in Survival Extrapolations Across Therapeutic AreasBart Heeg, Dawn Lee, Jane Adam, et al.
Pharmacoeconomics|April 1, 2025
A Hemophilia Joint Health Score-Based Model for the Economic Evaluation of Hemophilia A Prophylaxis InterventionsSam Hirniak, Andrea N Edginton, Alfonso Iorio, et al.
Pharmacoeconomics|October 29, 2025
A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry DataAdam Irving, Dennis Petrie, Anthony Harris, et al.
Pharmacoeconomics|September 24, 2025
Eladocagene Exuparvovec for the Treatment of Aromatic L-Amino Acid Decarboxylase Deficiency (AADCd): An Economic Evaluation from a US PerspectiveRongrong Zhang, Thomas O'Connell, Berrin Monteleone, et al.
Pharmacoeconomics|August 19, 2025
Eliciting and Anchoring Health State Preferences Using Discrete Choice Experiments Among Adults, Adolescents, and ChildrenShitong Xie, Tianxin Pan, Juan Manuel Ramos-Goni, et al.
Pharmacoeconomics|September 9, 2025
HTA Evidence in Rare Diseases: Just Rare or Also Special?Anirban Basu, Simu K Thomas, Richard H Chapman, et al.
Pharmacoeconomics|September 12, 2025
Heterogeneity in Economic Value of SGLT2is for Type 2 Diabetes: Subgroup Modeling Cost-Effectiveness AnalysesKah Suan Chong, Chun-Ting Yang, Chi-Chuan Wang, et al.
Pharmacoeconomics|August 7, 2025
Evaluating the Role and Policy Implications of Using External Evidence in Survival Extrapolations: A Case Study of Axicabtagene Ciloleucel Therapy for Second-Line DLBCLSam Harper, Daniela Afonso, Karina Watts, et al.
Pharmacoeconomics|July 27, 2025
Can We Make Health Economic Decision Models as Simple as Possible, But Not Simpler? Introducing SMART toolTeebah Abu-Zahra, Sabine E Grimm, Mirre Scholte, et al.
Pharmacoeconomics|July 29, 2025
The Cost-Effective Price of Lecanemab for Patients with Early Alzheimer's Disease in SwedenXin Xia, Sandar Aye, Oskar Frisell, et al.
Pageof 336